Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
Authors
Keywords
Denosumab, Fracture threshold, Hip bone mineral density, Long-term osteoporosis therapy, Nonvertebral fracture, Treatment to goal
Journal
OSTEOPOROSIS INTERNATIONAL
Volume 26, Issue 12, Pages 2763-2771
Publisher
Springer Nature
Online
2015-06-11
DOI
10.1007/s00198-015-3179-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Differing effects of denosumab and alendronate on cortical and trabecular bone
- (2013) Roger M. Zebaze et al. BONE
- Assessment of incident spine and hip fractures in women and men using finite element analysis of CT scans
- (2013) David L Kopperdahl et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The Effect of Three or Six Years of Denosumab Exposure in Women With Postmenopausal Osteoporosis: Results From the FREEDOM Extension
- (2013) Henry G. Bone et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Impact of Nonhip Nonvertebral Fractures in Elderly Women and Men
- (2013) Dana Bliuc et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Denosumab Significantly Increases DXA BMD at Both Trabecular and Cortical Sites: Results From the FREEDOM Study
- (2012) Michael A. Bolognese et al. JOURNAL OF CLINICAL DENSITOMETRY
- Bisphosphonates for Osteoporosis — Where Do We Go from Here?
- (2012) Marcea Whitaker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
- (2012) M. R. McClung et al. OSTEOPOROSIS INTERNATIONAL
- Decreased bone remodeling and porosity are associated with improved bone strength in ovariectomized cynomolgus monkeys treated with denosumab, a fully human RANKL antibody
- (2011) Paul J. Kostenuik et al. BONE
- Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys
- (2011) Michael S. Ominsky et al. BONE
- Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
- (2011) Matthew Austin et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension
- (2011) Socrates Papapoulos et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)
- (2011) Dennis M Black et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density
- (2010) H.K. Genant et al. BONE
- Mortality Risk Associated With Low-Trauma Osteoporotic Fracture and Subsequent Fracture in Men and Women
- (2009) Dana Bliuc JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
- (2009) Steven R. Cummings et al. NEW ENGLAND JOURNAL OF MEDICINE
- Excess mortality following hip fracture: a systematic epidemiological review
- (2009) B. Abrahamsen et al. OSTEOPOROSIS INTERNATIONAL
- Theoretical Implications of the Biomechanical Fracture Threshold
- (2008) Tony M Keaveny et al. JOURNAL OF BONE AND MINERAL RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now